Showing results (1031-1040 of 3,716) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|April 7, 2022
Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGADaniel Tobias Michaeli, Mackenzie Mills, Thomas Michaeli, et al.
Investigational New Drugs|April 18, 2022
Signature constructed by glycolysis-immune-related genes can predict the prognosis of osteosarcoma patientsKangsong Tian, Wei Qi, Qian Yan, et al.
Investigational New Drugs|April 18, 2022
Effects of rifampicin on antineoplastic drug pyrotinib maleate pharmacokinetics in healthy subjectsMing-Min Cai, Ting Dou, Lu Tang, et al.
Investigational New Drugs|March 21, 2022
The kinesin Eg5 inhibitor K858 exerts antiproliferative and proapoptotic effects and attenuates the invasive potential of head and neck squamous carcinoma cellsAlice Nicolai, Samanta Taurone, Simone Carradori, et al.
Investigational New Drugs|October 6, 2021
Zerumbone acts as a radiosensitizer in head and neck squamous cell carcinomaJulia Schnoell, Isabella Stanisz, Bernhard J Jank, et al.
Investigational New Drugs|February 3, 2022
First-in-human trial exploring safety, antitumor activity, and pharmacokinetics of Sym013, a recombinant pan-HER antibody mixture, in advanced epithelial malignanciesJordan Berlin, Anthony W Tolcher, Cliff Ding, et al.
Investigational New Drugs|February 24, 2022
The therapeutic potential of RNA Polymerase I transcription inhibitor, CX-5461, in uterine leiomyosarcomaChang-Won Kang, Katherine M Hannan, Anneke C Blackburn, et al.
Investigational New Drugs|November 1, 2021
A phase I study of the tyrosine kinase inhibitor anlotinib combined with platinum/pemetrexed-based chemotherapy in untreated nonsquamous non-small-cell lung cancerMeijuan Huang, Yongmei Liu, Min Yu, et al.
Investigational New Drugs|June 25, 2019
Phase II trial of continuous treatment with sunitinib in patients with high-risk (BCG-refractory) non-muscle invasive bladder cancerHaris Zahoor, Maria C Mir, Pedro C Barata, et al.
Investigational New Drugs|June 25, 2019
A phase I dose-reduction study of apatinib combined with pemetrexed and carboplatin in untreated EGFR and ALK negative stage IV non-squamous NSCLCMeijuan Huang, Youling Gong, Jiang Zhu, et al.
Pageof 372